IND Application filed for First in Class Senolytic Immunotherapy SenoVax™ for Treatment of Advanced Lung Cancer
“To our knowledge, this is the first clinical candidate to push the immune system to attack not the cancer itself, but the cells protecting it,” said Thomas Ichim, PhD, President and Chief Scientific Officer of Immorta Bio. “In contrast to cancer, which mutates in a very rapid manner, senescent cells surrounding the tumor do not mutate, thus making them a more attractive therapeutic target. While the primary aim of the study is not to investigate systemic effects, it will be of significant interest to observe any additional regenerative benefits of the SenoVax therapy, beyond its impact on tumor size reduction.”
Share:
More News
“Between 2017 and 2023, the socioeconomic burden of HER2-positive breast cancer in ten major economies was nearly $590 billion, projected to increase to nearly $1,000 billion by 2032,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “At-home treatment may help alleviate the pressure
Richard Saynor, CEO of Sandoz, said: “The global burden of cancer continues to grow and the potential to address unmet patient needs has never been greater. This agreement offers us the chance to reach many more millions of patients, while helping to drive the long-term sustainability of healthcare systems.”
“Beyond the second-line monotherapy opportunity, we and our partners at Pfizer have removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan,” continued Dr. Houston. “This decision was made following
“The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.”
